Cybin Inc. (HELP)
AI stock analysis · as of Jun 25, 2026
Loading microstructure…
Cybin Inc. (dba Helus Pharma, ticker HELP) is a clinical-stage neuropsychiatry company developing psychedelic-based therapeutics, with lead asset CYB003 (deuterated psilocybin) in Phase 3 for major depressive disorder and CYB004 (deuterated DMT) in Phase 2 for generalized anxiety. With zero revenue, ~$113M annual net loss, and ~$135M cash post a $50M raise, the core investment question is binary: do the Phase 3 MDD readouts (expected 2026) validate the platform, or does the company dilute its way through trial completion with uncertain commercial outcome?
valuationExpensive on conventional metrics (P/B 115x, negative EV/EBITDA, no revenue) but valuation is essentially a real option on Phase 3 success — traditional multiples are not meaningful for a pre-revenue biotech.
This analysis is from Jun 25, 2026. Want the latest on HELP, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Phase 3 trial for CYB003 in MDD is the most advanced deuterated psilocybin program in development; positive readout in 2026 could rerate the stock dramatically given the multi-billion-dollar MDD TAM
- · Recent $50M raise extends runway; with $135M cash and zero debt, the company has financial flexibility to reach key Phase 3 milestones
- · Strong Wall Street conviction: 8 analysts with strong_buy consensus and mean target of $42.73 vs current $6.04 implies ~600% upside if thesis plays out
- · Diversified pipeline beyond CYB003 (CYB004 Phase 2 anxiety, SPL028, SPL026, CYB005) provides multiple shots on goal
- · Institutional ownership at 53.9% suggests sophisticated investors believe in the platform thesis
- · Stock trades near 52-week low ($3.76) and well below highs ($9.83), offering asymmetric setup ahead of Phase 3 catalyst
Bear case
- · Zero revenue with widening losses: net loss expanded from -$47M (2023) to -$78M (2024) to -$113M (2025); FCF of -$103M implies cash burn that will require additional dilutive raises before any approval
- · P/B of 115x reflects almost all value being optionality on clinical success — any Phase 3 setback could collapse the equity
- · Psychedelic therapeutics face uncertain regulatory and commercialization pathway (DEA scheduling, REMS, payer reimbursement) even with positive trial data
- · Recent $50M equity raise already dilutive; given -$103M FCF run-rate, more raises are likely well before 2026 readout
- · ROE of -55.9% and negative EV/EBITDA highlight there is no fundamental valuation floor — this is a binary clinical bet
- · News coverage is sparse and concentrated in a single source, suggesting limited market awareness/liquidity could amplify volatility
Catalysts
- · CYB003 Phase 3 MDD trial readouts expected in 2026 — the dominant value driver
- · CYB004 Phase 2 generalized anxiety disorder data progression
- · Additional financing announcements (likely dilutive given burn rate)
- · FDA interactions, breakthrough designation updates, or regulatory milestones for the deuterated psilocybin platform
- · Short ratio of 3.61 days-to-cover is moderate; positive trial data could trigger a modest squeeze
- · Next earnings on 2026-06-26 — likely coinciding with pipeline updates
Key risks
- · Phase 3 trial failure or mixed efficacy data would likely cause a >70% drawdown given pre-revenue status
- · Cash runway: at -$103M FCF, current $135M cash lasts ~15 months absent further raises, forcing continued dilution
- · Regulatory risk specific to scheduled psychedelics; even approval may carry restrictive labeling/REMS
- · Competition from Compass Pathways, MindMed, atai, and reformulated SSRIs/ketamine could compress commercial opportunity
- · Low insider ownership (3.7%) suggests limited management skin in the game
- · Small float and sparse coverage create liquidity/volatility risk on either direction
What to watch
- · CYB003 Phase 3 enrollment progress and any interim safety/futility readouts
- · Cash burn trajectory in next quarterly filings and any signs of pending capital raises
- · Next earnings/update on 2026-06-26 for pipeline timelines
- · Key technical levels: 52-week low $3.76 (support) and $9.83 (resistance)
- · Analyst rating revisions — currently no upgrades/downgrades in 90d; any shifts among the 8 covering analysts
- · Insider transaction filings — 2 transactions in 180d with net zero sells; watch for direction change
Key metrics
Price target rationale
Base case ($8) reflects modest re-rating as Phase 3 readout approaches, blending ~30% probability of success at ~$25 and ~70% probability of dilution/setback at ~$2-3. Bull case ($25) assumes positive Phase 3 interim signals and de-risking, aligning with mid-range analyst targets. Bear case ($2) reflects further dilutive raises and/or pipeline setbacks before 2026 readout. Targets reflect option-value framework appropriate for pre-revenue clinical-stage biotech.
On Wall Street's view (disagree): The $42.73 consensus target implying ~600% upside appears to fully price in Phase 3 success and ignores dilution risk and execution timeline; while the upside scenario could justify such a target, a probability-weighted view warrants a substantially lower base case given the binary clinical risk.
What the news says · neutral
The only directly relevant news for Helus Pharma (HELP) is a US$50M equity raise, with multiple Stock Titan items confirming the pricing of a share sale to fund a Phase 3 MDD (major depressive disorder) trial and anxiety programs, with results expected in 2026. While the capital raise signals the company has secured runway to advance its NSA pipeline into late-stage trials — a positive development for pipeline progression — share sales are dilutive to existing shareholders, which tempers the bullish read. Coverage is sparse and concentrated in a single source (Stock Titan), with the vast majority of other headlines being entirely unrelated to HELP. The net effect is modestly positive for pipeline credibility but dilution risk keeps sentiment near neutral.
This analysis is from Jun 25, 2026. Markets move. Get the current read on HELP and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.